Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Feb 1;70(2):437-41.
doi: 10.1016/j.ijrobp.2007.06.050. Epub 2007 Sep 19.

Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02

Colleen A Lawton  1 , Kyoungwha Bae, Miljenko Pilepich, Gerald Hanks, William Shipley
Affiliations
Clinical Trial

Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02

Colleen A Lawton et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: Late gastrointestinal (GI) and genitourinary (GU) morbidity from external beam irradiation used to treat adenocarcinoma of the prostate continue to be a concern of physicians and patients alike. In addition, for locally advanced/high-risk cancer, the appropriate use of hormonal manipulation in addition to radiation therapy (RT) may increase toxicity. We analyzed three large Radiation Therapy Oncology Group (RTOG) studies (85-31, 86-10, and 92-02) to try to address these issues.

Methods and materials: A total of 2,922 patients were accrued with a median follow-up of 10.3 years for surviving patients. The RTOG scoring scheme was used to assess GI, GU, and other toxicities. Toxicity reported was Grade 3 or higher late toxicity. Patient toxicity level was assessed by study and by treatment type combining RT only vs. RT + short-course hormone therapy (STH) vs. RT + long-term hormone therapy (LTH).

Results: Multivariate analysis reveals that age >70 was statistically significantly associated with a decrease in late any Grade 3+ toxicity (hazard ratio [HR] = 0.78, p = 0.0476) adjusted for treatment type. Comparing treatment type, patients treated with RT+STH had a statistically significant lower probability of Grade 3+ GI, GU, and other toxicity compared with RT alone (p = .00006; p = 0.0037; p = 0.0127, respectively). Patients treated with RT+LTH had a statistically significant lower probability of Grade 3+ GU toxicity compared with RT alone (p = 0.023).

Conclusions: These data show that external beam radiation therapy remains a safe option for locally advanced/high-risk prostate cancer, and the use of hormonal manipulation does appear to be protective for GU and GI toxicity depending upon length of treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None

Figures

Figure 1
Figure 1
Time to Late Grade 3+ GI Toxicity By Treatment Type
Figure 2
Figure 2
Time to Late Grade 3+ GU Toxicity By Treatment Type
Figure 3
Figure 3
Time to Late Grade 3+ Other Toxicity By Treatment Type
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the RTOG and EORTC. Int J Rad Onc Biol Phys. 1995;31:1341–1346. - PubMed
    1. Lawton CA, Won M, Pilepich M, et al. Long-term treatment sequelae following external beam radiation for adenocarcinoma of the prostate: Analysis of RTOG studies 75-06 and 77-06. Int J Rad Onc Biol & Phys. 1991;21:935–939. - PubMed
    1. Pilepich M, Winter K, Lawton C, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long term results of phase III RTOG 85-31. Int J Rad Onc Biol & Phys. 2005;61(5):1285–1290. - PubMed
    1. Pilepich M, Winter K, John M, et al. Phase III RTOG trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Rad Onc Biol & Phys. 2001;50(5):1243–1252. - PubMed
    1. Hanks G, Pajak T, Porter A, et al. Phase III trial of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: RTOG protocol 92-02. J Clin Onc. 2003;21(21):3972–3978. - PubMed

Publication types

MeSH terms